Top 3 Health Care Stocks That Could Blast Off This Month
This article identifies three oversold healthcare stocks—Veracyte Inc (VCYT), Akso Health Group (AHG), and Inogen Inc (INGN)—that could present buying opportunities. These companies have a Relative Strength Index (RSI) near or below 30, indicating they may be undervalued. Recent news affecting each company, including earnings and R&D initiatives, are highlighted.
CPAP Store USA Adds New Inogen Aurora CPAP Mask Line
CPAP Store USA has launched Inogen's new Aurora CPAP Mask Collection, becoming the first authorized online and in-store retailer for these non-magnetic masks. This expansion introduces three mask interfaces—F1 Full Face, N1 Nasal, and P1 Nasal Pillows—offering greater choice and comfort for CPAP and BiPAP users. The move signifies a notable expansion for both companies, with Inogen entering sleep therapy and CPAP Store USA broadening its respiratory care offerings.
Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$12.67
Inogen, Inc. (NASDAQ:INGN) reported quarterly results last week, showing revenues of US$95m and losses of US$0.14 per share, which were better than analyst expectations. Following the earnings, analysts maintained their loss per share estimates for 2026 but downgraded revenue forecasts, expecting Inogen to grow slower than the broader industry. Despite the revenue downgrade, analysts lifted their price target for Inogen by 8.6% to US$12.67 per share, suggesting an improvement in the company's intrinsic value.
Dimensional Fund Advisors LP Reduces Position in Inogen, Inc $INGN
Dimensional Fund Advisors LP significantly reduced its stake in Inogen, Inc. by 28.3% in the first quarter, selling over 200,000 shares but still retaining a substantial holding. Despite this reduction, other institutional investors have increased their positions, and Inogen's stock holds a "Moderate Buy" consensus rating from analysts, even after a reiterated "sell" rating from Weiss Ratings. The company recently reported a narrower-than-expected quarterly loss, though revenue slightly missed forecasts, with analysts anticipating a full-year loss of $0.77 per share.
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
Inogen, Inc. (INGN) has lowered its 2026 revenue outlook due to persistent U.S. channel pressure, specifically a decline in direct sales and rentals, despite strong international growth and improved profitability. The company expects 2026 revenues to be between $355 million and $361 million, a reduction from previous estimates. Inogen is focusing on business-to-business efforts and new products like the Voxi stationary oxygen concentrator to adapt to the changing market.
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen (INGN) trades at a significant discount compared to its industry peers, driven by improved Q2 2026 margins and strong international demand. While the company boasts a debt-free balance sheet and expanding respiratory offerings, persistent weakness in U.S. direct sales and rentals presents execution risks. The current low valuation combined with mixed operational signals suggests a cautious "hold" stance for investors.
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
Inogen, Inc. (INGN) has lowered its 2026 revenue outlook due to persistent U.S. channel pressure, despite experiencing better profitability and international growth in the second quarter. The company is facing a shift in the U.S. oxygen market towards portable oxygen concentrators as initial therapy, impacting its direct-to-consumer sales, while international sales continue to grow. Inogen is expanding its business-to-business efforts and new product offerings like Voxi stationary oxygen concentrators and Aurora CPAP masks to offset these challenges.
Inogen Launches First CPAP Mask Portfolio
Inogen Inc. has launched its Aurora CPAP mask portfolio in the United States, marking its entry into the obstructive sleep apnea market. This expansion aims to leverage existing distribution channels to offer a variety of mask designs—F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows—to meet diverse patient needs. The company reports high patient satisfaction with the comfort and performance of the new masks, which are seen as a key growth catalyst in Inogen's strategy to become a broader home healthcare respiratory solutions provider.
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
Inogen reported breakeven earnings for Q2 2026, beating estimates, with revenues of $95.1 million, up 3% year over year, driven by strong international demand and new products. However, the company cut its full-year 2026 revenue guidance to $355-$361 million due to continued U.S. sales channel mix pressure. Despite this, Inogen is focused on expanding its respiratory care portfolio and expects to launch at least one new product annually.
Inogen Launches Voxi 5 Stationary Oxygen Concentrator
Inogen Inc. has launched the Voxi 5, a new stationary oxygen concentrator (SOC) developed with Yuwell Medical, to expand access to oxygen therapy for long-term care patients in the US. This device provides 1-5 liters per minute of continuous flow oxygen, offering a compact and mobile solution designed for affordability and to complement Inogen's portable oxygen concentrator line. The Voxi 5 aims to serve price-sensitive customers and those needing additional units for multi-room use, reinforcing Inogen's commitment to accessible respiratory care.
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
Inogen (INGN) reported breakeven earnings for Q2 2026, surpassing estimates, with revenues rising 3% year-over-year to $95.1 million, driven by strong international demand and new products. Despite this, the company cut its full-year 2026 revenue guidance to $355-$361 million, down from previous estimates, due to continued U.S. sales channel mix pressure and timing of international distributor purchases. The company continues to focus on expanding its respiratory care portfolio and international presence.
Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$12.67
Following Inogen, Inc.'s recent earnings report, analysts reconfirmed their loss per share estimates but downgraded revenue forecasts for 2026, predicting slower growth than the broader industry. Despite this, the consensus price target was lifted to US$12.67, suggesting analysts see an improvement in the company's intrinsic value.
Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$12.67
Inogen, Inc. (NASDAQ:INGN) reported quarterly results last week, with revenues of US$95m matching predictions and statutory losses coming in 8.7% smaller than expected at US$0.14 per share. Following the report, analysts reconfirmed their loss per share estimates for next year but downgraded revenue estimates, forecasting slower growth than the broader industry. Despite the revenue downgrade, analysts increased their price target by 8.6% to US$12.67 per share, suggesting an improvement in the company's intrinsic value.
Arrowstreet Capital Limited Partnership Acquires 393,310 Shares of Inogen, Inc $INGN
Arrowstreet Capital Limited Partnership significantly increased its stake in Inogen, Inc. by 203.9% in the first quarter, purchasing 393,310 additional shares, bringing its total holdings to 586,159 shares. This makes Arrowstreet Capital own 2.16% of the medical technology company, with institutional investors collectively holding 89.94% of the stock. Despite a recent quarterly loss per share, Inogen's revenue exceeded expectations, and the stock currently holds a "Moderate Buy" consensus rating from analysts.
Inogen (NASDAQ:INGN) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
Inogen (NASDAQ:INGN) reported quarterly earnings, beating expectations with a loss of $0.14 per share against a projected $0.15 loss. While revenue slightly missed estimates at $95.08 million, the company showed improved profitability with a 15% rise in adjusted EBITDA and strong international sales growth. Despite reducing full-year revenue guidance due to U.S. direct-channel pressures, Inogen increased its full-year adjusted EBITDA outlook, driven by new product traction and international expansion.
Inogen (INGN) Has a New Rating from B. Riley Securities
B. Riley Securities initiated coverage on Inogen (INGN) with a Buy rating and a $14.00 price target, following Needham's Buy rating and $12.00 price target for the stock. Inogen reported a quarterly revenue of $95.08 million and a GAAP net loss of $3.85 million for the quarter ending June 30, showing improved financial performance compared to the previous year. This article includes syndicated content and notes that The Globe and Mail has not reviewed or endorsed it.
Inogen Inc Q2 2026: Revenue $95.08M, EPS $(0.14) — 10-Q Summary
Inogen Inc. reported Q2 2026 revenue of $95.08M and diluted EPS of $(0.14), marking modest top-line growth and improved margins. The company's net loss narrowed to $3.85M from $4.15M a year prior, driven by higher unit volumes and favorable foreign exchange, particularly in international sales. Gross margin also improved to 46.2% due to manufacturing leverage and lower chip premium costs.
Inogen, Inc. (INGN) Stock Price, News, Quote & History
This Yahoo Finance page provides detailed financial information for Inogen, Inc. (INGN), a medical technology company specializing in respiratory health products. It includes real-time stock quotes, historical data, key financial metrics, performance overview, earnings trends, analyst insights, and comparison tools with similar companies in the medical devices industry.
Inogen Inc (INGN) (Q2 2026) Earnings Call Highlights: Strong International Growth and New ...
Inogen Inc. (INGN) reported strong international revenue growth of 15% year-over-year and core POC unit volume growth of over 12% in Q2 2026, with new products Voxy and Aurora gaining traction. Despite these positive indicators and an expanded gross margin, the company lowered its full-year 2026 revenue guidance due to declining U.S. sales and rental revenue, reflecting channel mix challenges and a structural market shift. Inogen maintains a strong balance sheet and increased its adjusted EBITDA guidance, while actively addressing the U.S. market headwinds and exploring new product opportunities.
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
Inogen (INGN) reported a Q2 loss of $0.14 per share, which was better than the Zacks Consensus Estimate of a $0.17 loss, and also surpassed revenue estimates with $95.08 million. Despite underperforming the S&P 500 year-to-date, the company's stock currently holds a Zacks Rank #3 (Hold), indicating an expected performance in line with the market. Investors are advised to monitor management's commentary and future estimate revisions.
Inogen Inc earnings beat by $0.03, revenue topped estimates
Inogen Inc (NASDAQ: INGN) reported its second-quarter earnings, beating analyst EPS estimates by $0.03 with an EPS of $-0.14. The company also surpassed revenue expectations, bringing in $95.1M against a consensus estimate of $95.05M. Despite the beat, the stock has seen a -7.83% decline in the last three months, though it is up 10.22% over the last year, with its financial health rated as "good performance" by InvestingPro.
Inogen, Inc Revenue Breakdown – NASDAQ:INGN
Inogen, Inc. (NASDAQ: INGN) generated $348.67 million USD in revenue last year. The primary driver of this revenue was the Oxygen Concentrators and Related Accessories segment, contributing $295.30 million USD. Geographically, the United States was the largest contributor to the company's revenue, accounting for $209.84 million USD.
Inogen Inc (INGN) Cash Flow
This article provides a detailed cash flow statement for Inogen Inc (INGN), outlining quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics such as net income, capital expenditures, and free cash flow, along with year-over-year percentage changes. The article also features an FAQ section explaining various cash flow components and their significance for investors.
INGN|Inogen Inc|Price:6.405|Chg%:+0.255
This article provides a detailed company profile for Inogen Inc (INGN), a medical technology company specializing in respiratory products like portable oxygen concentrators. It covers the company's background, business scope, key products such as the Inogen One and Inogen Rove systems, and executive information. The article also touches on market performance, shareholder details, and institutional holdings.
INGN|Inogen Inc|Price:6.150|Chg%:-0.170
This article provides a detailed financial overview of Inogen Inc. (INGN), including its stock performance, key financial indicators like EPS, revenue, and net profit from quarterly and annual reports, and a summary of balance sheet and cash flow statements. It highlights the company's latest earnings date, EPS and revenue forecasts, and an "Analyst Rating" of BUY.
Inogen Inc (INGN) Income Statement
This article provides a detailed quarterly and annual income statement for Inogen Inc (INGN), outlining key financial metrics such as total revenue, cost of revenue, operating expenses, and net income. It also includes an FAQ section to help users understand how to interpret these financial statements and identifies important metrics for analyzing INGN stock. The data covers financial periods from FY2012Q3 through FY2026Q1, highlighting trends in the company's financial performance.
Inogen Inc (INGN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Inogen Inc (INGN), detailing its current valuation score, market capitalization, and P/E ratio. As of July 24, 2026, the company's valuation score is 8.91, placing it 58th in the Healthcare Equipment & Supplies industry. The article notes that several key valuation metrics like P/B, P/S, and P/CF have not been disclosed by the company yet.
Inogen Inc (INGN) Institutional Confidence
Inogen Inc (INGN) has an institutional shareholding score of 7.00, placing it 79th in the Healthcare Equipment & Supplies industry. Institutional investors hold 75.89% of shares, a 4.39% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, with 2.35% of outstanding shares.
INGN|Inogen Inc|Price:6.310|Chg%:+0.160
This article provides a comprehensive stock analysis of Inogen Inc (INGN), highlighting its relatively healthy fundamentals, high growth potential, and current valuation as "fairly valued" within the Healthcare Equipment & Supplies industry. Despite recent weak stock market performance, the company exhibits strong fundamentals and high institutional ownership. Analysts have rated it as a "Buy" with a target price of $12.00, suggesting the stock price is expected to remain stable in the medium term.
Inogen to report Q2 2026 results after market close, host conference call
Inogen (NASDAQ: INGN) has scheduled the release of its second-quarter 2026 financial results for August 6, 2026, after the market closes. The company will also host an earnings call on the same day at 2 p.m. PT (5 p.m. ET), with a webcast available through its investor relations website. This announcement was created using generative AI based on content originally published by Inogen via Business Wire.
Inogen to report second quarter 2026 results on August 6
Inogen will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. The medical technology company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss its performance. Investors can access the live webcast or a replay, which will be available until August 13, 2026.
Press Release: Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026
Inogen is scheduled to report its second-quarter 2026 financial results on August 6, 2026, after the market closes. The company will also hold a conference call and live webcast to discuss these results on the same day. Investors can access the webcast or dial into the call for participation.
Inogen (INGN) Stifel 2024 Healthcare Conference Summary
Inogen (INGN) shared a summary of their Stifel 2024 Healthcare Conference, detailing efforts in leadership and culture transformation under new CEO and CFO focused on growth, profitability, and innovation. The company is rebaselining its DTC business for profitability, scrutinizing costs, and enhancing B2B channel growth through improved relationships and digital health initiatives. All channels are being optimized for profitability, with improved DTC profitability expected in the latter half of the next year.
Form 4 Inogen Inc For: 9 July By Investing.com
This article reports on a Form 4 filing for Inogen Inc (IGN) relating to transactions on July 9, 2026. The brief piece indicates that Inogen Inc. has a stock symbol INGN and includes its current performance at the time of publication. The content primarily serves as a notification of a regulatory filing.
Inogen (INGN) EVP, COO awarded 130,000 restricted stock units vesting from 2026
Inogen Inc.'s EVP and COO, Andrew P. Reding, has been granted 130,000 restricted stock units (RSUs). These RSUs will begin vesting on September 1, 2026, with one-third vesting after one year and the remaining units vesting in equal annual installments, contingent on his continued employment. This equity award aims to align the executive's compensation with the company's long-term performance.
Inogen (INGN) EVP, COO Andrew Reding files baseline Form 3 insider report
Inogen Inc.'s EVP and COO, Andrew P. Reding, has filed an initial Form 3 with the SEC, establishing his status as an insider with the company. This filing is a baseline report of beneficial ownership and does not indicate any purchases, sales, or other transactions of company shares or derivatives. The document confirms his officer role and the requirement to periodically disclose ownership information.
Form 4 Inogen Inc For: 9 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Inogen Inc. on July 9th. Form 4 filings disclose changes in beneficial ownership of securities, often indicating insider trading by company officers, directors, or significant shareholders. The article is very brief and seems to be a placeholder for a more detailed report on the specific transactions.
Inogen Inc (INGN) executive sells 10,938 shares in planned trade
Jennifer M. Yi Boyer, EVP Enterprise Enablement and Chief HR Officer at Inogen Inc (INGN), sold 10,938 shares of company common stock for $6.5959 per share on July 1, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. Following the sale, Yi Boyer directly holds 5,039 shares of Inogen common stock.
Inogen (INGN) Proxy Filing Summary
Inogen (INGN) has announced its annual meeting scheduled for May 14, 2025, where shareholders will vote on the election of three Class II director nominees, the ratification of Deloitte & Touche LLP as independent auditor, and the approval of executive compensation and an amended equity incentive plan. Shareholders can participate virtually and are encouraged to vote by May 13, 2025. The board recommends approval for all director nominees.
INGN - Inogen Inc Volatility & Greeks
This article provides a detailed overview of Inogen Inc (INGN) financial data, including its stock performance, volatility metrics, and various financial ratios. It covers key figures such as market capitalization, sales, earnings per share, insider and institutional ownership, and analyst recommendations, offering a comprehensive snapshot of the company's current financial health and market position.
Inogen Appoints New Chief Operating Officer for Growth
Inogen has appointed Andy Reding as its new Chief Operating Officer, a move aimed at strengthening its leadership and execution capabilities to support diversification, new product launches, and geographic expansion. Reding brings over 30 years of experience in medical technology and respiratory care. His compensation package includes a substantial base salary, performance-based bonus, and restricted stock units, with severance protections designed to attract and retain senior talent.
Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
Inogen, Inc. (Nasdaq: INGN) has appointed Andy Reding as its new Chief Operating Officer, a newly created role aimed at strengthening leadership and driving commercial and operational execution. Reding brings over 30 years of medical technology and commercial operations experience, previously serving as Chief Commercial Officer at Viant Medical and Vice President and GM at Hillrom Respiratory Health. His appointment is expected to help Inogen diversify its business, enhance execution, and accelerate strategic priorities, including driving top-line growth and expanding the innovation pipeline.
Inogen Appoints Reding to New COO Role
Inogen has appointed Jason Reding as its new Chief Operating Officer, a newly created role within the company. Reding brings extensive experience in general management, operations, and supply chain across various industries, including medical devices. This strategic hire is expected to strengthen Inogen's operational execution and global supply chain management.
Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
Inogen, Inc. has announced the appointment of Andy Reding as Chief Operating Officer, a newly created role effective July 6, 2026. Reding will be responsible for driving revenue, operational performance, and aligning strategic priorities to enhance execution and accelerate the company's growth. With over 30 years of leadership experience in medical technology, including significant respiratory care expertise, Reding is expected to be instrumental in Inogen's diversification and expansion efforts.
Inogen appoints Andy Reding as chief operating officer
Inogen Inc. has appointed Andy Reding as its new Chief Operating Officer, a newly created position aimed at strengthening its leadership structure. Reding brings over 30 years of experience in medical technology and will be responsible for revenue and operational performance, aligning cross-functional priorities, and translating company strategy into operational outcomes. The company also announced that Reding will receive an inducement equity award of restricted stock units covering 130,000 shares of Inogen’s common stock.
Inogen Inc SEC Filing
This SEC Form 144 filing indicates a proposed sale of 10,770 shares of Inogen Inc. (INGN) common stock by Jennifer Yi Boyer, dated May 29, 2026, under a 10b5-1 plan. The filing also notes 10,938 Restricted Stock Units acquired on March 1, 2025, with Morgan Stanley Smith Barney LLC identified as the broker. The aggregate market value of the shares to be sold is reported as $70,550.10.
Inogen (Nasdaq: INGN) adds COO Andy Reding with equity package
Inogen (Nasdaq: INGN) has appointed Andy Reding as its new Chief Operating Officer, effective July 6, 2026, a newly created role to drive revenue, operations, and cross-functional execution for new products and geographic expansion. Reding's compensation package includes a $500,000 annual base salary, a 70% target bonus, a $100,000 sign-on bonus, and an equity award of 130,000 time-based Restricted Stock Units (RSUs) vesting over three years. The appointment aims to strengthen Inogen's leadership as it diversifies its business and advances its respiratory care strategy.
Inogen, Inc. Financial Disclosures & Filings
This page provides a comprehensive list of Inogen, Inc.'s financial disclosures and filings, including earnings reports, annual general meetings, corporate presentations, and investor conference transcripts from 2022 to 2026. These documents offer insights into the company's financial performance, strategic initiatives, and growth drivers, crucial for informed investment decisions.
Inogen, Inc. Actuals & Estimates (NASDAQ:INGN)
This article provides an overview of Inogen, Inc.'s (NASDAQ: INGN) financial actuals and estimates, including its current stock price, historical performance, analyst forecasts, and upcoming earnings report. It highlights the company's financial data, such as market capitalization, EBITDA, and net income, alongside frequently asked questions about its stock. The content also includes details on volatility, employee count, and guidance on how to trade INGN shares.
Inogen, Inc. Actuals & Estimates (SWB:6IO)
This article provides financial actuals and estimates for Inogen, Inc. (SWB:6IO), including income statement, balance sheet, and cash flow data, alongside analyst price targets. It details the company's past earnings and revenue, future earnings report dates, and key financial metrics like EBITDA. The article also addresses frequently asked questions regarding the stock, such as its ticker, forecast, historical prices, and dividend policy.
